• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测基于干扰素的治疗丙型肝炎病毒患者的预后生物标志物:NS5A 蛋白在 1a、1b 和 3a 亚型中的荟萃分析。

Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a.

机构信息

Informatics and Systems Department, Division of Engineering Research, National Research Centre, Tahrir Street, Cairo, Egypt.

出版信息

Virol J. 2010 Jun 15;7:130. doi: 10.1186/1743-422X-7-130.

DOI:10.1186/1743-422X-7-130
PMID:20550652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3238222/
Abstract

BACKGROUND

Hepatitis C virus (HCV) is a worldwide health problem with no vaccine and the only approved therapy is Interferon-based plus Ribavarin. Response prediction to treatment has health and economic impacts, and is a multi-factorial problem including both host and viral factors (e.g: age, sex, ethnicity, pre-treatment viral load, and dynamics of the HCV non-structural protein NS5A quasispecies). We implement a novel approach for extracting features including informative markers from mutations in the non-structural 5A protein (NS5A), specifically its Interferon sensitivity determining region (ISDR) and V3 regions, and use a novel bioinformatics approach for pattern recognition on the NS5A protein and its motifs to find biomarkers for response prediction using class association rules and comparing the predictability of the different features.

RESULTS

A total of 58 sequences from sustained responders and 94 from non-responders were downloaded from the HCV LANL database. Site-specific signatures for response prediction from the NS5A protein were extracted from the alignments. Class association rules were generated (e.g.: sustained response is associated with position A2368T in subtype 1a (support 100% and confidence 52.19%); in subtype 1b, response is associated with E2356G/D/K (support 76.3% and confidence 67.3%).

CONCLUSION

The V3 region was a more accurate biomarker than the ISDR region. Subtype-specific class association rules gave better support and confidence than profile hidden Markov models HMMs scores, genetic distances or number of variable sites, and would thus aid in the prediction of prognostic biomarkers and improve the accuracy of prognosis. Sites-specific class association rules in the V3 region of the NS5A protein have given the best support and confidence.

摘要

背景

丙型肝炎病毒(HCV)是一个全球性的健康问题,目前尚无疫苗,唯一批准的治疗方法是基于干扰素加利巴韦林。治疗反应的预测对健康和经济都有影响,是一个多因素问题,包括宿主和病毒因素(如年龄、性别、种族、治疗前病毒载量和 HCV 非结构蛋白 NS5A 准种动力学)。我们提出了一种从非结构 5A 蛋白(NS5A)中的突变中提取特征的新方法,特别是其干扰素敏感性决定区(ISDR)和 V3 区,并使用一种新的生物信息学方法对 NS5A 蛋白及其基序进行模式识别,以找到用于反应预测的生物标志物,使用类关联规则,并比较不同特征的可预测性。

结果

从 HCV LANL 数据库中下载了 58 个持续应答者和 94 个无应答者的序列。从 NS5A 蛋白的比对中提取了用于反应预测的位点特异性特征。生成了类关联规则(例如:1a 亚型中持续应答与位置 A2368T 相关(支持 100%,置信度 52.19%);在 1b 亚型中,反应与 E2356G/D/K 相关(支持 76.3%,置信度 67.3%))。

结论

V3 区比 ISDR 区更准确的生物标志物。亚型特异性类关联规则比 HMM 评分、遗传距离或可变位点数量提供了更好的支持和置信度,因此有助于预测预后生物标志物并提高预后的准确性。在 NS5A 蛋白的 V3 区的特定位置的类关联规则提供了最佳的支持和置信度。

相似文献

1
Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a.预测基于干扰素的治疗丙型肝炎病毒患者的预后生物标志物:NS5A 蛋白在 1a、1b 和 3a 亚型中的荟萃分析。
Virol J. 2010 Jun 15;7:130. doi: 10.1186/1743-422X-7-130.
2
[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].[在使用或不使用利巴韦林进行干扰素治疗前对丙型肝炎病毒NS5A区域的ISDR和V3结构域进行突变分析]
Pathol Biol (Paris). 2004 Nov;52(9):505-10. doi: 10.1016/j.patbio.2004.07.011.
3
Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.丙型肝炎病毒1型准种与聚乙二醇干扰素和利巴韦林的治疗结果
Infect Genet Evol. 2009 Jul;9(4):689-98. doi: 10.1016/j.meegid.2008.11.001. Epub 2008 Nov 21.
4
Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.在诱导和联合抗病毒治疗期间对全长丙型肝炎病毒NS5A准种进行前瞻性特征分析。
J Virol. 2000 Oct;74(19):9028-38. doi: 10.1128/jvi.74.19.9028-9038.2000.
5
NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.NS5A(ISDR-V3) 区域遗传变异性与突尼斯 HCV-1b 株对联合干扰素/利巴韦林治疗反应的相关性。
J Med Virol. 2009 Dec;81(12):2021-8. doi: 10.1002/jmv.21641.
6
Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.丙型肝炎病毒1b亚型NS5A基因的突变与阿塞拜疆患者对聚乙二醇干扰素α-2a/利巴韦林联合治疗的反应
Arch Virol. 2014 Nov;159(11):2893-9. doi: 10.1007/s00705-014-2133-0. Epub 2014 Aug 20.
7
Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.丙型肝炎病毒1型E2-PePHD、NS5A-PKRBD、NS5A-ISDR和NS5A-V3的突变及其与聚乙二醇干扰素-利巴韦林治疗反应的关系。
J Virol. 2008 Jul;82(13):6644-53. doi: 10.1128/JVI.02231-07. Epub 2008 Apr 30.
8
Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.丙型肝炎病毒1b型NS5A区域在干扰素或干扰素-利巴韦林联合治疗期间的准种进化
World J Gastroenterol. 2007 Feb 28;13(8):1195-203. doi: 10.3748/wjg.v13.i8.1195.
9
Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.丙型肝炎病毒 1a、1b、3a、3b、6f 基因型核心和 NS5A 基因的突变与聚乙二醇干扰素和利巴韦林联合治疗应答的相关性。
J Viral Hepat. 2011 Apr;18(4):e117-25. doi: 10.1111/j.1365-2893.2010.01379.x. Epub 2010 Oct 19.
10
Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.丙型肝炎1b型感染患者中干扰素敏感性决定区(非结构5A氨基酸2209 - 2248)的突变以及与聚乙二醇化干扰素和利巴韦林联合治疗反应的相关性。
Aliment Pharmacol Ther. 2008 Jan 1;27(1):72-9. doi: 10.1111/j.1365-2036.2007.03560.x. Epub 2007 Oct 25.

引用本文的文献

1
Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors.噻吩脲衍生物作为一类新型丙型肝炎病毒进入抑制剂。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):462-468. doi: 10.1080/14756366.2020.1870456.
2
In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes.靶向多种丙型肝炎病毒基因型保守区域的小干扰RNA的计算机设计与实验验证
PLoS One. 2016 Jul 21;11(7):e0159211. doi: 10.1371/journal.pone.0159211. eCollection 2016.
3
Hepatitis C virus infection: Are there still specific problems with genotype 3?

本文引用的文献

1
Natural genetic engineering of hepatitis C virus NS5A for immune system counterattack.
Ann N Y Acad Sci. 2009 Oct;1178:173-85. doi: 10.1111/j.1749-6632.2009.05003.x.
2
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.三种用于预测HIV联合治疗病毒学反应的计算建模方法的比较
Artif Intell Med. 2009 Sep;47(1):63-74. doi: 10.1016/j.artmed.2009.05.002. Epub 2009 Jun 12.
3
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.丙型肝炎病毒非结构蛋白5A的序列变异可预测聚乙二醇化干扰素/利巴韦林联合治疗的临床疗效。
丙型肝炎病毒感染:基因型3是否仍存在特定问题?
World J Gastroenterol. 2015 Nov 14;21(42):12101-13. doi: 10.3748/wjg.v21.i42.12101.
4
Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population.巴基斯坦人群丙型肝炎病毒 3a 基因型感染患者对干扰素治疗反应中 PKRBD 的研究。
Virol J. 2013 Dec 9;10:352. doi: 10.1186/1743-422X-10-352.
5
Viral quasispecies evolution.病毒准种进化。
Microbiol Mol Biol Rev. 2012 Jun;76(2):159-216. doi: 10.1128/MMBR.05023-11.
6
Identification of novel conserved functional motifs across most Influenza A viral strains.鉴定大多数甲型流感病毒株中新型保守功能基序。
Virol J. 2011 Jan 27;8:44. doi: 10.1186/1743-422X-8-44.
Hepatology. 2008 Jul;48(1):38-47. doi: 10.1002/hep.22339.
4
Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment.丙型肝炎病毒以及干扰素敏感性决定区在干扰素治疗反应中的争议性作用。
J Med Virol. 2008 Feb;80(2):247-53. doi: 10.1002/jmv.21060.
5
The Pfam protein families database.Pfam蛋白质家族数据库。
Nucleic Acids Res. 2008 Jan;36(Database issue):D281-8. doi: 10.1093/nar/gkm960. Epub 2007 Nov 26.
6
MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0.MEGA4:分子进化遗传学分析(MEGA)软件版本4.0。
Mol Biol Evol. 2007 Aug;24(8):1596-9. doi: 10.1093/molbev/msm092. Epub 2007 May 7.
7
Viral determinants of resistance to treatment in patients with hepatitis C.丙型肝炎患者治疗耐药性的病毒决定因素。
Clin Microbiol Rev. 2007 Jan;20(1):23-38. doi: 10.1128/CMR.00010-06.
8
MUMMALS: multiple sequence alignment improved by using hidden Markov models with local structural information.MUMMALS:通过使用具有局部结构信息的隐马尔可夫模型改进的多序列比对。
Nucleic Acids Res. 2006;34(16):4364-74. doi: 10.1093/nar/gkl514. Epub 2006 Aug 26.
9
Two Sample Logo: a graphical representation of the differences between two sets of sequence alignments.双样本标识:两组序列比对之间差异的图形表示。
Bioinformatics. 2006 Jun 15;22(12):1536-7. doi: 10.1093/bioinformatics/btl151. Epub 2006 Apr 21.
10
Review article: predicting response in hepatitis C virus therapy.综述文章:预测丙型肝炎病毒治疗的反应
Aliment Pharmacol Ther. 2006 Apr 15;23(8):1043-54. doi: 10.1111/j.1365-2036.2006.02863.x.